When seizures continue despite treatment

When two appropriate antiseizure medication schedules have failed to achieve sustained seizure freedom, the answer should not simply be an endless sequence of medication changes without specialist reassessment.

Why two treatment failures matter

The ILAE definition is deliberately specific. A medicine has to be appropriate for the seizure type or epilepsy syndrome, used properly, tolerated well enough to complete an adequate trial, and still fail to produce sustained seizure freedom.

After two appropriate treatment failures, the probability that repeated medication changes alone will eventually produce lasting seizure freedom becomes much lower. NICE therefore treats this point as a trigger for tertiary specialist assessment, not as a reason to keep trying medicines indefinitely without revisiting the whole diagnosis and treatment strategy.

Drug-resistant does not mean untreatable

Drug-resistant epilepsy means antiseizure medication has not achieved the goal of sustained seizure freedom. It does not mean that nothing else can help, that surgery will definitely be needed, or that every available medicine has already been tried.

Depending on the epilepsy, specialist options can include a more detailed diagnostic review, resective epilepsy surgery, vagus nerve stimulation, other forms of neuromodulation, ketogenic dietary therapy, syndrome-specific treatments or further medication strategies.

Not every apparent medicine failure is true drug resistance

Before labelling epilepsy drug-resistant, clinicians need to ask whether the treatment really had a fair chance to work. Apparent resistance can occur when:

• the original diagnosis is wrong or incomplete
• events are not all epileptic seizures
• the seizure type or epilepsy syndrome has been misclassified
• the medicine chosen can worsen that seizure type
• the dose was too low or treatment too brief
• side effects prevented an adequate trial
• doses were missed or treatment was stopped repeatedly
• drug interactions or absorption problems reduced effective exposure
• sleep loss, alcohol, illness or other triggers were repeatedly provoking seizures

This is sometimes described clinically as pseudo-resistance: seizures appear treatment-resistant, but a correctable factor is preventing treatment from being properly tested.

A tertiary epilepsy review can change the diagnosis

Specialist reassessment may include a detailed seizure history, witness descriptions or videos, prolonged or video EEG, epilepsy-protocol MRI, medication history, neuropsychological testing and review of whether all recorded events are truly epileptic.

Some people referred with “refractory epilepsy” are found to have more than one event type, including dissociative or functional seizures alongside epilepsy. Others have a focal structural cause that was not obvious on earlier imaging.

Surgery should not be treated as a last resort after years of delay

NICE recommends discussing assessment for resective epilepsy surgery with people who have drug-resistant epilepsy and referring them for specialist assessment — including people whose MRI does not show a clear abnormality.

NICE also recommends considering earlier referral when MRI shows abnormalities associated with a high risk of drug resistance, including hippocampal sclerosis, malformations of cortical development, epilepsy-associated low-grade tumours, hypothalamic hamartomas, tuberous sclerosis complex, vascular malformations and some previous brain injuries.

The ILAE Surgical Therapies Commission went further in a 2022 international expert consensus statement: referral for surgical evaluation should be offered to every person with drug-resistant epilepsy as soon as drug resistance is established, provided there is no clear contraindication to evaluation.

Referral for surgery does not mean agreeing to surgery

A surgical referral is an assessment pathway, not a commitment to an operation. The purpose is to find out whether seizures arise from a brain region that can be treated safely and whether the likely benefits outweigh risks to memory, language, movement, vision and other functions.

Even if surgery is eventually ruled out, the assessment may improve seizure classification, reveal a previously unrecognised cause, optimise medication or identify another treatment option.

What does presurgical assessment involve?

The exact pathway varies, but it may include prolonged video EEG, high-resolution MRI, neuropsychological testing, functional imaging such as PET or SPECT, language and memory assessment, and sometimes invasive EEG using electrodes placed on or within the brain.

The central question is whether the seizure-generating network can be treated with an acceptable balance between seizure control and neurological risk.

Resective epilepsy surgery

For suitable people with drug-resistant focal epilepsy, resective surgery aims to remove the brain tissue responsible for generating seizures. Examples include lesionectomy and temporal lobe surgery, although the exact procedure depends on seizure origin and anatomy.

NICE’s evidence review concluded that resective epilepsy surgery is the most clinically effective treatment for appropriately selected children, young people and adults with drug-resistant focal epilepsy, with better seizure outcomes and quality of life than continued medical care alone.

Vagus nerve stimulation (VNS)

If resective surgery is not suitable, NICE recommends considering vagus nerve stimulation as an add-on treatment to antiseizure medication.

VNS uses an implanted pulse generator connected to the vagus nerve in the neck. Its usual aim is to reduce seizure frequency or severity rather than guarantee seizure freedom. Response varies between people and may build gradually over time.

Deep brain stimulation and other neuromodulation

Deep brain stimulation (DBS) uses implanted electrodes to stimulate selected brain targets. NICE has guidance on DBS for refractory epilepsy in adults and notes that it may be considered for some people when resective surgery is not indicated.

Other neuromodulation systems exist internationally, including responsive neurostimulation (RNS), which detects abnormal electrical activity and delivers stimulation in response. Availability varies substantially by country and healthcare system, so these should not be presented as universally available options.

Ketogenic dietary therapy

NICE recommends considering a ketogenic diet under a tertiary epilepsy specialist for certain childhood-onset epilepsy syndromes and for drug-resistant epilepsy when other treatment options have been unsuccessful or are not appropriate.

This is a medically supervised therapy, not simply a low-carbohydrate diet. It can interact with medicines and affect growth, nutrition, kidney stones, lipids and gastrointestinal health, so specialist dietetic support is important.

Medication still matters after drug resistance is recognised

Reaching the drug-resistant definition does not mean antiseizure medicines are abandoned. Some people still achieve meaningful seizure reduction with later medicines or combinations, and medication usually continues alongside surgery, VNS, DBS or dietary therapy.

The key change is that medication should no longer be the only strategy being considered.

Why uncontrolled seizures matter beyond seizure count

Persistent seizures can affect injury risk, driving, employment, education, memory, mood, sleep, independence and relationships. Frequent generalised tonic-clonic or focal-to-bilateral tonic-clonic seizures are also important risk factors for epilepsy-related mortality, including SUDEP.

That is why timely specialist review is not merely about improving convenience or reducing medication burden. For some people it may reduce serious long-term risk.

Quality of life matters too

Seizure freedom is an important goal, but treatment decisions also consider medication side effects, cognition, mood, fatigue, independence and the burden of repeated hospital visits or injuries. A treatment that reduces seizures but causes intolerable adverse effects may not represent a good outcome for that person.

Questions worth asking at review

• Have I genuinely failed two adequate, appropriate medication schedules?
• Is my seizure type and epilepsy syndrome still considered correct?
• Could any of my events be non-epileptic?
• Has my MRI been reviewed using an epilepsy protocol?
• Should I be referred to a tertiary epilepsy centre?
• Should I have an epilepsy surgery assessment?
• If resection is not suitable, could VNS or another neuromodulation treatment help?
• Is ketogenic dietary therapy relevant to my epilepsy?
• What is the realistic aim of the next treatment — seizure freedom, fewer seizures, shorter seizures, fewer injuries, or better quality of life?

Related specialist pages

Epilepsy Surgery and Presurgical Assessment · Vagus Nerve Stimulation · DBS, RNS and Other Neurostimulation · Remission, Seizure Freedom and Resolved Epilepsy

Sources and guidance

International League Against Epilepsy — Definition of drug-resistant epilepsy

NICE NG217 — Drug-resistant epilepsy definition

NICE NG217 — Ketogenic diet, resective surgery and VNS

ILAE Surgical Therapies Commission — Timing of referral for epilepsy surgery

NICE — Deep brain stimulation for refractory epilepsy in adults

Explore treatment options →

Medical note: Drug resistance is a treatment definition, not a prediction that every future treatment will fail. Specialist reassessment is important because diagnosis, seizure classification and candidacy for non-drug treatments can all change the next step.